StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > CC

<< Previous

Bullboard Posts

Next >>

Comment by NewToInvesting7on Aug 17, 2021 12:19pm

183 Views

Post# 33717201

RE:RE:CC

I wasn't sure if he was talking about 100,000 patients "qualified" and "lined up", or whether he was merely talking about interest from 100,000 patients through the TREAT program on the website.

What I found interesting is his comment "we are now ready to start taking payment for the AVRT Aristotle cancer test" - this was around the 20 minute mark.

davewho wrote: sure sounds like James says at around the 19 min mark that they have over 100,000 patients that are waiting for the Avrt program to begin.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale